Welcome to our dedicated page for Icu Medical news (Ticker: ICUI), a resource for investors and traders seeking the latest updates and insights on Icu Medical stock.
ICU Medical reports news on its global medical-device business in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate-site and home-care settings. Company updates commonly cover quarterly results, fiscal guidance, GAAP and non-GAAP profitability measures, and revenue trends across the Consumables, Infusion Systems and Vital Care product lines.
Recurring announcements also include earnings-call schedules, investor conference participation and business changes that affect reported comparisons, including the completed divestiture of the IV Solutions business. The company’s news flow centers on product-line performance, margin trends, adjusted EBITDA, adjusted diluted earnings per share and management commentary on operating results.
ICU Medical reported second quarter 2020 revenues of $303.4 million, a decrease from $312.3 million in Q2 2019. The GAAP gross profit rose to $106.3 million, yielding a gross margin of 35%. Net income fell to $18.9 million or $0.88 per diluted share, down from $22.8 million or $1.06 per share a year prior. Adjusted diluted EPS decreased to $1.65 from $1.99. Demand for infusion pumps remained strong amid the COVID-19 pandemic.
ICU Medical, Inc. (Nasdaq:ICUI) announced its Q1 2020 financial results, revealing a revenue of $328.6 million, down from $330.9 million in Q1 2019. The company's GAAP gross profit decreased to $121.4 million, yielding a gross margin of 37% compared to 41% last year. Net income fell to $16.8 million or $0.78 per share, down from $31.0 million or $1.44 per share in the previous year. Adjusted EBITDA also declined to $63.0 million, from $77.9 million. The company revised its full-year guidance for adjusted EBITDA and EPS downward due to external economic factors.